We regret to inform you that the Phase 1b clinical trial evaluating RTX-134 in patients with phenylketonuria has been discontinued. To learn more about Rubius Therapeutics and its therapeutic areas of focus, please visit: https://www.rubiustx.com/our-pipeline/#therapeutic-areas.
Sincerely, The Patient Advocacy Team at Rubius Therapeutics
Continue to Site
At Rubius, our vision is to bring potentially life-changing cellular therapies to people living with cancer and autoimmune diseases. We call these potential medicines Red Cell Therapeutics™.
Learn About Red Cell Therapeutics™
Find a Clinical Trial
If you consent to Rubius Therapeutics contacting you about information related to its Red Cell Therapeutics and clinical trials, please check the boxes below.
We will contact you about your submission